We speculate that 5aza-dC and other DNMT inhibitors might serve as excellent epigenetic modifiers and adjuvants to our current therapeutic regimens to limit cellular plasticity in prostate cancer. The gene discussed is DNMT1; the disease is Familial prostate cancer.